Topical ivermectin cream (10 mg/g) and systemic, oral anti-inflammatory doxycycline (40 mg modified-release) are both approved for the treatment of papulopustular rosacea (PPR). Whether or not a combined therapeutic approach may be more beneficial than monotherapy for patients with PPR remains to be tested. Here, we summarize underlying inflammatory pathways implicated in rosacea and clarify the impact of these two agents on selective pathways during inflammation, due to specific characteristics of their individual mechanisms of action (MoA). Based on the complementary MoA of doxycycline modified-release and ivermectin, a scientific rationale for a combined therapy targeting inflammatory lesions in rosacea is given. We propose that topical ivermectin cream is a promising new candidate as first-line treatment to target the inflammatory lesions of rosacea, which can be used in combination with systemic doxycycline modified-release to provide an optimal treatment approach considering all inflammatory pathways involved in PPR. Funding Galderma.
INTRODUCTION
Rosacea is a chronic inflammatory disease characterized by the presence of various signs and symptoms including flushing (transient erythema), persistent erythema, inflammatory papules and pustules (inflammatory lesions), telangiectasia, skin irritation (burning and stinging), etc. These signs and symptoms can occur in isolation or combination [1, 2] .
Recommendations for the classification of rosacea into four subtypes based on clinical presentation were proposed in 2002, as follows: erythematotelangiectatic rosacea (ETR); papulopustular rosacea (PPR); phymatous rosacea (PYR); and ocular rosacea (OR). However, patients usually present with a spectrum of symptoms overlapping these subtypes [1, 2] . For example, although PPR is characterized by the presence of lesions (papules, pustules), patients may also additionally present with persistent erythema [2] , and if the papules/pustules are cured, the erythema still remains. Furthermore, PYR is observed after or at the same time as PPR and erythema (either transient or persistent) [3, 4] .
Symptoms may vary from one week to the next, making the disease unpredictable, which can affect the patient's quality of life [2, 5] . Finally, scientific evidence indicates that the erythema observed in ETR is an inflammatory process and the underlying cause demands anti-inflammatory therapy [6] [7] [8] [9] [10] . Signs and symptoms of rosacea often appear to be triggered by environmental factors, including sun exposure, temperature change, stress, spicy foods, and heavy exercise [11, 12] .
Recent epidemiological studies have indicated that rosacea also has a genetic component [6, 13] . Affected rosacea skin exhibits increased sensitivity to these triggers [14] ; for example, compared with people with non-lesional skin, individuals with PPR have a significantly lower threshold for temperature-induced pain, resulting in facial hypersensitivity [15] . This is thought to be due to a hyper-responsive immune system and increased levels of proteins involved in inflammatory pathways [14] . Neurovascular and neuro-immune dysregulation may contribute to erythematous changes (flushing, erythema) in rosacea patients, which can impact innate and adaptive immune defense mechanisms [6] [7] [8] [9] ;
whether the autonomic or sensory nervous system (or both) is crucial for the mediation of flushing or erythema is still under debate [16, 17] . A link has also been established between the presence of high levels of
Demodex mites (such as D. folliculorum and D. brevis) and rosacea, with signs and symptoms of rosacea potentially resulting from heightened pro-inflammatory skin response [18] [19] [20] [21] [22] [23] [24] . [7, 8, 12] . During the inflammatory process in rosacea, chronic inflammation results in prolonged vasodilation, allowing fluid to leak out. This, in turn, causes edema, infiltration of leukocytes and production of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-a), interleukin (IL)-1, and IL-6, which eventually leak into the dermis [35] . This vascular leakage attracts additional neutrophils, which are recruited by chemotactic factors released from inflamed dermal structures [35] . Leukocytes release nitric oxide (NO), matrix metalloproteinases (MMPs), and reactive oxygen species (ROS), which contribute to chronic vasodilation and dermal matrix degradation [35, 36] . Significantly elevated levels of ROS are responsible for the initiation of several pro-inflammatory processes in the skin, including expression of leukocyte-attracting chemokines, C-C motif chemokine ligand 2 (CCL2), and C-X-C motif chemokine 8 (CXCL8) [37] . During this process, pro-inflammatory cytokines such as TNF-a and IL-1 become upregulated, promoting leukocyte chemotaxis [37] . In addition, the leakage of pro-inflammatory cytokines such as TNF-a and IL-1 into the dermis triggers production of secondary chemokines (including CXCL1, CXCL8, CCL20, and CCL27) in keratinocytes, leading to T cell recruitment into the perifollicular space, contributing to disease progression [37] . Rosacea skin may be more sensitive to specific triggers due to irregular expression of certain proteins, such as toll-like receptor-2 (TLR2), serine protease kallikrein (KLK), and [33] , and Steinhoff et al. [16] abnormal forms of cathelicidin [2, 29] .
Signaling via TLRs upregulates the vitamin D receptor, causing induction of the cathelicidin pathway [34, 38] and increased expression of TLR2, which in turn induces a calcium-dependent increase KLK5 levels in keratinocytes and subsequent increase in serine protease activity by KLK5 [29, 33] . KLK5 activity and post-translational processing cleaves the C-terminal cathelin domain of the inactive precursor of cathelicidin, hCAP18, to give rise to the active peptide LL-37 [36] .
Increased cathelicidin expression in rosacea skin promotes leukocyte infiltration and stimulates angiogenesis [30] . MMP cleavage/ activation of KLK5 indirectly catalyzes the proteolytic activation of hCAP18 to LL-37; therefore, MMP activation of KLK5 can increase the levels of LL-37, leading to increased inflammation [36] . Inhibition of KLK5 has been linked with a reduction in the occurrence of papules and erythema severity, providing further evidence of this pathway in the pathogenesis of rosacea [39] . This has recently been demonstrated in a clinical setting, with patients with PPR treated with doxycycline 40 mg modified-release showing a decrease in both gene expression and protein levels of MMPs, KLK, and cathelicidin, which resulted in a reduction in inflammatory lesion count and consequently improved clinical outcomes [40] .
Mast cells have also been implicated in the pathophysiology of rosacea, with the number of mast cells shown to be elevated in the dermis of rosacea patients presenting with different subtypes [7, 32] . When mast cells in the skin are activated, they secrete proteases such as chymase, tryptase, KLK5, and MMPs, which induce dermal inflammation and increase the production of enzymes in the epidermal layer that generate LL-37, thereby creating a pro-inflammatory loop [32, 41] . In the skin, mast cells are primarily found in the epidermis and dermis in close proximity to keratinocytes and sensory nerves endings; the secretion of proteases, histamine, and pro-inflammatory cytokines by mast cells contributes to the amplification of the skin inflammation, tissue remodeling, and angiogenesis [32] . Increased stratum corneum permeability has been linked to an aggravated innate immune response [26] , with barrier impairment causing skin sensitivity in patients with rosacea [42] .
Elevated levels of serine proteases can contribute to stratum corneum permeability barrier dysfunction [14] . The innate immune system may be activated as a homeostatic counter-regulatory response to impaired stratum corneum barrier, resulting in increased trans-epidermal water loss (TEWL), and increased expression and secretion of cathelicidin (LL-37) [14] . Compared with control subjects, patients with both PPR and ETR have increased TEWL and heightened reactivity to skin irritation using lactic acid [43] . Individuals with PPR have also been found to have reduced epidermal hydration and a more alkaline centro-facial region compared with controls [44] .
Adaptive Immune System Response
The adaptive immune system has been shown to contribute to inflammation in several inflammatory dermatoses including acne [45] (including Il12rb1 and Ccr5) were significantly elevated in PPR, indicating a Th1-polarized immune response in rosacea [8] .
Elevated levels of antibody-producing B cells can be found in patients with PPR or PYR [8] ;
however, the role of B cells in the pathogenesis of rosacea has yet to be fully elucidated. Ivermectin has a similar structure to macrolide antibiotics [57, 58] ; however, its use is not associated with the development of antibiotic resistance [59, 60] . As a semi-synthetic derivative of avermectin (macrocyclic lactones) [57, 58] , oral ivermectin has been used as an anti-parasitic since the 1970 s [61] [62] [63] , and is associated with reduction of levels of mites, such as Demodex mites, on the skin [55, 64] .
TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA
In vitro and in vivo studies have also demonstrated that oral ivermectin strongly reduces the priming of specific effector T cells (Ventre et al., submitted), and accumulation of neutrophils and monocytes [65] .
Oral ivermectin also acts further downstream in inflammatory pathways, having previously been shown to inhibit lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines, including TNF-a, IL-1, and IL-6 [66] , through the inhibition of the nuclear factor kappa B (NF-jB) pathway [66] . Ivermectin is able to suppress production of the inflammatory mediators NO and prostaglandin E2 (PGE2), and reduce inducible NO synthase (iNOS) and cyclooxygenase-2 (COX2) mRNA expression levels by inhibiting phosphorylation of the mitogen-activated protein kinases (MAPK) p38, extracellular-signal-regulated kinase (ERK) 1/2, and c-Jun N-terminal kinase (JNK) [67] . NO can generate or modify intracellular signals, thereby affecting the function of immune cells [67] . The modulation of NO, iNOS, COX2, and PGE2 release are major contributing factors during the inflammatory process. Inhibition of NO and PGE2 production by ivermectin results from the inhibition of iNOS and COX2 gene expression [67] . The MoA of ivermectin is yet to be fully elucidated, but a proposed MoA has been derived from the current preclinical evidence (Fig. 2) . Further studies will be needed to confirm this proposed MoA.
Recently, the anti-inflammatory effects of topical ivermectin have been demonstrated in clinical trials, as shown by decreased counts of inflammatory lesions [59, 68] , although further studies will be required to confirm the exact anti-inflammatory effects of topical ivermectin in PPR.
Phase III clinical trials have been conducted, investigating the efficacy and safety of ivermectin 10 mg/g cream in the treatment of inflammatory lesions of rosacea. In two studies, Stein Gold et al. [59] Metronidazole is also indicated for use against inflammatory lesions of rosacea and is known to target inflammation by decreasing ROS levels through scavenging and inactivation, and inhibiting production of these free oxygen radicals, which helps to protect the skin from damage [73] . An investigator-blinded, randomized, parallel-group study was conducted to demonstrate the superiority of ivermectin cream versus metronidazole 7.5 mg/g cream twice daily (metronidazole cream) in patients with moderate or severe inflammatory lesions of rosacea [68] . Ivermectin cream was found to be significantly superior to metronidazole cream in reducing inflammatory lesion counts from 3 weeks of treatment initiation, with a good safety profile [68] . Following this superiority study, patients who were initially successfully treated with ivermectin cream or metronidazole cream (i.e., 'clear' or 'almost clear', IGA 0 or 1) were enrolled to an extension study, in which the study treatment was discontinued [74] . Length of remission was monitored and patients were only re-treated with the initial agent if they presented with an IGA C2 during the 36-week extension [74] . Overall, ivermectin cream significantly extended remission of disease compared with initial treatment with metronidazole cream following treatment Fig. 2 Proposed targets of ivermectin in the inflammatory pathways in rosacea. Overview of molecular and cellular targets of ivermectin (green triangle). Ivermectin is an anti-parasitic, which is known to target Demodex mites, which can be found at increased levels in patients with rosacea. Ivermectin also inhibits multiple pro-inflammatory cytokines, including IL-1b, IL-6, and TNF-a; and inflammatory mediators such as NO, COX2, and PGE2. Tetracyclines are a class of antibiotics that includes the second-generation derivatives doxycycline, minocycline, and lymecycline [76, [80] [81] [82] [83] , which have broad-spectrum activity [76] . Antibiotics were first widely prescribed by dermatologists in the 1950s, when it was discovered that they were effective in the treatment of acne [82] . Doxycycline and minocycline were approved in 1966 and 1973, respectively [76] ; and have an improved bioavailability, longer elimination half-life and can be administered with food, which minimizes GI side effects [82] . Tetracyclines have been demonstrated to: downregulate the production of the pro-inflammatory cytokines IL-1 and TNF-a; inhibit neutrophil chemotaxis; inhibit the production of NO, ROS, and MMPs [76, 80] Although antibiotics have been a mainstay treatment for the inflammatory lesions of rosacea, there is increasing concern regarding the development of antibiotic resistance with prolonged use of these agents, which could potentially result in adverse global health consequences [76] . There has been a call to minimize or discontinue routine and regular use of antibiotics in the treatment of skin diseases such as acne and rosacea [84] .
Tetracyclines are the most commonly prescribed type of oral antibiotic, with doxycycline accounting for approximately one-third of prescriptions, and over the past three decades, bacterial resistance to tetracycline has increased [75] . Traditional doses of immediate-release doxycycline (C 50 mg) can exert selection pressure, increasing the risk of bacterial resistance [80] .
They can also alter the balance of commensal microflora, which can predispose patients to side effects such as vaginal candidiasis [80] . Doxycycline 50-200 mg is commonly prescribed off-label for rosacea based on its anti-inflammatory properties [76, 85] , which unnecessarily exposes patients to antibiotics [76, 84] . A prospective, placebo-controlled, randomized, double-blind trial in 29 healthy volunteers demonstrated that daily administration of oral doxycycline 100 mg was associated with a significant increase in doxycycline-resistant nasopharyngeal flora measured at Days 7 and 14, which continued for more than 2 weeks after cessation of therapy [86] . Daily treatment with doxycycline 100 mg has also been shown to induce microbial resistance as early as 7 days after the start of treatment [86] . stimulator of angiogenesis) [80, 90] . In addition, doxycycline 40 mg modified-release is a more potent inhibitor of MMPs than minocycline or tetracycline, acting as a non-competitive inhibitor of these enzymes [80] .
A recent study indicates that patients with rosacea may be at a higher risk of developing cardiovascular disease (CVD) [91] . MMPs have been shown to be influential in the pathology of both rosacea and CVD [92] , triggering an inflammatory pathway via production of KLK5 and cathelicidin and subsequent production of LL-37 [36] . Based on the fact that doxycycline 40 mg modified-release inhibits MMP activity, this agent could potentially also be beneficial in the prevention or reduction of CVD risk, as doxycycline has previously been shown to: defend capillary wall and connective tissue integrity; reduce hypersensitivity to vasodilatory stimuli; prevent leakage of capillaries: and inhibit cytokines involved in inflammation [92] . Furthermore, it has been observed that sub-antimicrobial-dose doxycycline (20 mg twice daily) lowers the levels of the inflammatory biomarker serum C-reactive protein (CRP), with elevated CRP Fig. 4 Proposed targets of doxycycline 40 mg modifiedrelease on inflammatory pathways in rosacea based on current evidence [14, 36, 76, 80, 94] . Overview of molecular and cellular targets of doxycycline 40 mg modified-release (orange circle). Doxycycline 40 mg modified-release acts on several targets in the cathelicidin pathway, including MMPs, KLKs (e.g., KLK5), and cathelicidin. It also acts on pro-inflammatory cytokines, including IL-1b, IL-8, and TNF-a; and inflammatory mediators such as ROS. IL interleukin, KLK kallikreins, MMPs matrix metalloproteinases, NO nitric oxide, PGE2 prostaglandin E2, ROS reactive oxygen species, TLR2 toll-like receptor 2, TNF tumor necrosis factor, VEGF vascular endothelial growth factor. Adapted from Del Rosso et al. [14] , Kanada et al. [36] , Di Nardo et al. [40] , Baldwin [76] , Fowler [80] , and Cazalis et al. [94] levels being a known CVD risk factor [93] . By inhibiting the production and activity of MMPs, doxycycline 40 mg modified-release blocks multiple inflammatory pathways, which inhibits the production of proteins contributing to the pathophysiology of PPR inflammation. This ultimately reduces the inflammation associated with inflammatory lesions of rosacea [36, 94] .
Although doxycycline 40 mg modified-release acts as an anti-inflammatory agent [76, 80] , it does not have antimicrobial activity [80, 95] , and does not exert selective pressure on microorganisms or encourage the development of bacterial resistance [76] . In a 9-month, multicenter, randomized, double-blind, placebo-controlled trial, subgingival samples were collected from adult patients with periodontitis at baseline and after 9 months of doxycycline 40 mg modified-release once-daily (n = 34) or placebo therapy (n = 36) [80, 96] .
Treatment with either doxycycline 40 mg modified-release or placebo did not result in the development of antibiotic resistance, and only a minor comparable increase in doxycycline-resistant bacteria was observed in both study arms after 9 months (5.09% vs. 5.38%, respectively; P = 0.965) [80, 96] .
In patients with rosacea, the efficacy and safety of doxycycline 40 mg modified-release (anti-inflammatory dose) has been investigated versus placebo [95] and doxycycline 100 mg [97] . In two trials, adult patients with inflammatory lesions (moderate to severe disease) were randomized to receive either doxycycline 40 mg modified-release (n = 269) or placebo (n = 268) once daily [95] . The mean total inflammatory lesion count of patients was 19.9 in Study 1 and 20.8 in Study 2 [95] . At Week 16, the mean change from baseline in inflammatory lesion counts in the active treatment groups was -11.8 in Study 1 and -9.5 in Study 2, compared with -5.9 and -4.3 in the placebo groups, respectively (P\0.001 for both comparisons) [95] . In addition, doxycycline 40 mg modified-release was well tolerated, with a similar number of AEs experienced by patients in both groups [95] . In a separate 16-week study, the efficacy and safety of doxycycline 40 mg modified-release was compared with those of doxycycline 100 mg, showing that reduction in inflammatory lesion counts from baseline was similar in the two groups; at Week 16, the mean change in inflammatory lesion counts from baseline was Table 1 and presented in Fig. 5 [ 36, 55, 64, 66, 80, 94] . Treatment efficacy could be increased if these two agents were used in combination, through a targeting of multiple steps of different inflammatory pathways.
Doxycycline 40 mg modified-release targets
MMPs and ROS, indirectly blocking production of inflammatory mediators [36, 80, 89] . Oral ivermectin has been shown to inhibit T cell activation, release of pro-inflammatory mediators, macrophage and neutrophil recruitment, as well as reducing levels of Demodex mites on the skin, which prevents the subsequent amplification of the inflammatory response [64] [65] [66] . In addition, these agents also act on several common targets, which further reduce the intensity of the inflammatory response. In a recent preclinical study, the synergistic activity of doxycycline and ivermectin was demonstrated to be effective in the complete eradication of body lice [98] . The hypothesis is that combining treatments which act on different targets within inflammatory pathways could provide improved results for patients with inflammatory lesions of rosacea.
Results from combination studies provide a rationale for the combinatorial use of agents in the treatment of inflammatory lesions of rosacea.
In a 16-week, randomized, Tick marks in black indicate that an agent acts on a specific target. Tick marks in green indicate that only either ivermectin or doxycycline acts on a specific target COX2 cyclooxygenase-2, IL interleukin, KLKs kallikreins, MAPK mitogen-activated protein kinases, MMPs matrix metalloproteinases, NO nitric oxide, PGE2 prostaglandin E2, ROS reactive oxygen species, TNF-a tumor necrosis factor alpha double-blind, placebo-controlled study, adult patients with inflammatory lesions of rosacea anti-inflammatory and sub-antimicrobial activity, has been shown to inhibit MMPs and suppress the production of KLK5, the cathelicidin peptide LL-37, as well as inhibit the production of certain pro-inflammatory cytokines [36, 94] . Both ivermectin 10 mg/g cream and doxycycline 40 mg modified-release have been shown to be clinically effective in reducing the number of inflammatory lesions in patients with PPR; in addition, both agents have a good safety profile [59, 68, 69, 95, 97] .
DISCUSSION
Based on the initial evidence of the efficacy of combinatorial therapies, both in rosacea [99] and in the treatment of other dermatological diseases such as acne [27] , the combination of topical ivermectin 10 mg/g cream with oral doxycycline 40 mg modified-release could provide an intensive initial regimen, especially for those patients with more involved disease or when a fast onset of action is required. Onset of treatment effect can be seen as early as 2 weeks after treatment initiation with ivermectin 10 mg/g cream monotherapy [59] and 3 weeks with doxycycline 40 mg modified-release monotherapy [95] ; onset of action could potentially be faster, with a potentially larger reduction in inflammatory lesions, if these agents were to be used in combination.
SUMMARY AND CONCLUSIONS
Given the chronic nature of rosacea, the need for continuous therapy often leads to reduced adherence in patients with this disease [76] . 
